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Editorial
New developments and controversies in cervical
cancer
This special issue of Reports of Practical Oncology and
Radiotherapy explores a wide range of issues surrounding the
treatment of cervical cancer (CC), which is the 4th most com-
mon cancer in women worldwide and is particularly prevalent
in underdeveloped and developing countries.1 Since the early
20th century, radiotherapy has been used as a curative intent
treatment in non-surgical cases and as an adjunct treatment
in the postoperative setting. Early radiotherapy techniques
consisted of orthovoltage X-rays and radium brachyther-
apy, which achieved 5-year survival rates of 30% in the
1930s, although treatment-related toxicity was substantial.2
Improvements in surgical techniques, together with the emer-
gence of cobalt-60 radiotherapy, further increased survival
rates, although the late complication rate remained signif-
icant. Subsequent advances in radiotherapy included the
development of linear accelerators, three-dimensional (3D)
planning procedures, and afterloading source projectors for
brachytherapy (initially for medium and low-dose rate sources
and later for high-dose rate [HDR] sources). These improve-
ments increased 5-year survival rates to 40–50%. At the end of
the 1990s, new developments included intensity-modulated
radiotherapy (IMRT) and 3D-planning for brachytherapy, with
a greater use of iridium sources for HDR and pulsed-dose
rate treatments.3 The concomitant use of cisplatin-based
chemotherapy with external beam radiotherapy (EBRT) fur-
ther increased 5-year survival rates by as much as 10%. At
present, chemotherapy plus radiotherapy is the treatment
of choice for large tumors (>4 cm).4 The clear association
between human papillomavirus (HPV) and CC, which was
identified as the leading cause of CC in recent decades, has
led to the development of highly-effective vaccines. Although
these vaccines are available in most developed countries, their
routine administration implies a substantial cost, an issue that
is explored in a cost analysis study presented in this issue.5
In recent years, there has been an exponential increase
in the number of procedures available to manage CC. At the
same time, new imaging techniques developed over the last
20 years have improved both the diagnosis and treatment of
this disease. These imaging techniques have been particularly
valuable to improve radiotherapy planning. Sentinel node
evaluation is now routinely included in surgical practice
to tailor pelvic lymphadenectomy in early stage disease to
reduce patient morbidity, as discussed in detail by Glickman
et al. in this special issue.6 Indeed, magnetic resonance
imaging (MRI) is now considered the gold standard for volume
definition in planning both EBRT and brachytherapy; in this
regard, this special issue includes two papers that describe
the imaging techniques for treatment planning in patients
with CC.7,8 At present, MRI and PET-CT are considered the
best imaging tools for patient follow-up. Moreover, pre- and
post-treatment imaging data obtained via MRI and PET-CT
can provide valuable information—together with molecular
markers—to better establish prognosis and predict treatment
outcomes.
Currently, IMRT is considered the optimal radiotherapy
approach to minimize treatment-related complications in
the postoperative setting. Although several clinical trials are
currently underway, numerous studies have already demon-
strated the benefits of IMRT for curative treatment.9 Despite
the many advantages of IMRT, this technique requires the
daily use of image-guidance (mainly in advanced, non-surgical
cases) to ensure accurate delivery of the radiotherapy.10 It
is highly likely that image-guided adaptive radiotherapy will
become more widespread in the near future. Soft tissue
matching remains under investigation.
The new European Society of Gynecological Oncology
(ESGO)–European Society for radiotherapy and Oncology
(ESTRO)–European Society of Pathology (ESP) guidelines for CC
describe the use of paraaortic irradiation and the benefits of
neoadjuvant/adjuvant chemotherapy, which are areas of con-
troversy in the treatment of CC. In this special issue, three
different articles address these treatment modalities.4,11–13
The results of the ongoing EMBRACE II, NRG GY006 (Phase II),
and INTERTECC trials are expected to resolve the current con-
troversies related to numerous different aspects of treatment
delivery, treatment related toxicity and multimodal treatment.
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Brachytherapy combined with EBRT is the most rele-
vant treatment in CC since it allows for the delivery of the
highest dose to the tumor, thus providing greater local con-
trol and improving survival with fewer complications versus
EBRT alone. After 2005, the Gynecological GEC-ESTRO working
group published guidelines for MRI-based volume definition
and for parametrial implantation. Several studies performed
by this working group established MRI image-guided adaptive
brachytherapy (IGABT) as the gold standard for the treatment
of CC given that this technique yields better local control
and survival than previously reported results using other
techniques, with fewer treatment-related complications.
Nonetheless, MRI-IGABT is much more time-consuming than
other techniques and needs an experience and highly-trained
team of radiation oncologists and physicists for proper imple-
mentation. One report in this issue describes the medical
outcomes and other aspects of this procedure, while two other
articles describe the radiobiological considerations related to
the combined doses from both treatments and strategies for
MRI-based endocavitary and interstitial reconstruction.14–16
One of the articles included in this issue describes newer
treatment techniques such as stereotactic body radiotherapy
(SBRT), which has several indications in CC (and is likely to
have additional indications in the near future). At present,
when brachytherapy is not feasible, SBRT appears to be a bet-
ter option than IMRT alone; moreover, SBRT is an excellent
option to treat nodal relapse.17
Combined treatment with immunotherapy and molecu-
lar therapies is currently being investigated to improve local
control and survival in both curative and palliative patients.
It appears likely that individualized treatment will be avail-
able in the near future. At present, neoadjuvant and adjuvant
chemotherapy should be considered investigational in CC,
which explains why chemotherapy is usually only considered
to treat recurrent disease.11,12,18 However, radiotherapy also
plays a role in recurrent CC in which SBRT and hyperther-
mia and intraoperative radiotherapy have all been used, as
discussed in two articles in this issue.19,20
We believe that readers will find that this special issue
of RPOR provides a comprehensive exploration of the main
aspects and controversies in the treatment of cervical cancer.
These articles have been written by experienced clinicians and
will undoubtedly provide readers with a greater understand-
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